Cure My Disease

Don't miss your cure!

 Log in / Sign up

The gatekeepers of tumors: scientists probe how blood vessels let immune cells in

NCT ID NCT03667612

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers at Centre Oscar Lambret are studying how immune cells get inside breast and colon tumors. They will analyze stored tumor samples from about 70 patients treated between 2005 and 2007, looking at genes and proteins on blood vessel cells that may control this process. The goal is to understand which immune cells enter, through which vessels, and by what mechanisms, so future treatments can better harness the immune system against cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers can map how blood vessel cells let immune cells into tumors, this could point toward new ways to boost the body's immune attack on breast and colon cancers.
What could go wrong
This is a retrospective lab study of stored samples, not a treatment trial. It may find correlations that do not hold up in living patients, and any new therapy would be years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Jan 2018

Finished

Oct 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with: * a breast cancer * a colorectal cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 18 and over * Confirmed histological diagnosis of breast carcinoma at localized or metastatic stage or colorectal cancer * Treated at the Oscar Lambret Center or the Henri Becquerel Center between 1/1/2005 and 31/12/2007 * Having undergone surgery for excision of the primary tumor and / or a metastasis * resected specimen available * Patients who gave their consent Exclusion Criteria: * History of other cancers * Breast or colic tumors with other histological profiles * Patient treated for breast or colonic recurrence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm colon carcinoma colonic neoplasm colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Colon cancer

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, France

  • Centre Oscar Lambret

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.